Matthew Walter, MD

Bone Marrow Transplant Specialist, Medical Oncologist

matthew walter

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Hematology, bone marrow transplant, myelodysplastic syndromes (MDS)

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, WashU Medicine

Board Certification

  • 1998: American Board of Internal Medicine
  • 2002: American Board of Internal Medicine, Hematology
  • 2002: American Board of Internal Medicine, Medical Oncology

Training

  • 1995 - 1998: Intern and Resident, Medicine, Johns Hopkins University, Baltimore, MD
  • 1998 - 2004: Clinical and Research Fellow, Hematology and Oncology, WashU Medicine, St. Louis, MO
  • 1999 - 2000: 1999 - 2000: Chief Resident, Johns Hopkins University, Baltimore, MD

Education

  • 1995: MD, Saint Louis University, St. Louis, MO

Research & Selected Publications

Research Interests

Identifying novel treatments for patients with myelodysplastic syndromes (MDS) through the discovery of gene mutations that occur in the genomes of hematopoietic cells from patients with MDS.

Research Publications

Modeling the evolutionary dynamics of clonal hematopoiesis
Authors:

Marzban S, Stiehl T, Xie Z, one or more additional authors omitted Walter MJ, one or more additional authors omitted West J

Journal & Year:

Nat Genet | 2026

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy
Authors:

Liu J, Tran D, Xue L, one or more additional authors omitted Walter MJ, one or more additional authors omitted Bolton KL

Journal & Year:

Nat Genet | 2025

U2af1 S34F and U2af1 Q157R myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice
Authors:

Alberti MO, Srivatsan SN, Shao J, one or more additional authors omitted Walter MJ

Journal & Year:

Res Sq | 2025

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Authors:

Gurnari C, Robin M, Adès L, one or more additional authors omitted Walter MJ, one or more additional authors omitted Cazzola M

Journal & Year:

Blood | 2025

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response
Authors:

Jacoby MA, Duncavage ED, Khanna A, one or more additional authors omitted Walter MJ

Journal & Year:

Leukemia | 2025

The DNA Methyltransferase Inhibitor 5-Aza-4'-thio-2'-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Authors:

Bertoli RM, Chung YJ, Difilippantonio MJ, one or more additional authors omitted Walter MJ, one or more additional authors omitted Aplan PD

Journal & Year:

Cancer Res | 2024

Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors:

Tran D, Beeler JS, Liu J, one or more additional authors omitted Walter MJ, one or more additional authors omitted Bolton KL

Journal & Year:

Clin Cancer Res | 2024

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts
Authors:

Liu ZS, Sinha S, Bannister M, one or more additional authors omitted Walter MJ, one or more additional authors omitted Nguyen HD

Journal & Year:

Cancer Res | 2024